obefazimod

targets

all catalysts(0)

nothing on the calendar yet

News(4)

• Abivax shares surge as worries subside over immune drug’s cancer risk
  According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
  biopharma_dive · 1mo ago
• STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
  Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
  stat · 1mo ago
• AbiVax falls as safety worries cloud ‘landmark’ immune drug results
  A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
  biopharma_dive · 2mo ago
• STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
  Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
  stat · 2mo ago